EXPEDITION 3: A phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer’s Disease
Our final scientific program is now online!
will be posted on Thursday, December 8 at 8:00 PT
Last chance to register CTAD will be sold out soon
Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge.
+ 33 (0)4 67 10 92 23